Get the Stockscreener App
0.9157
5.87%
0.0508
After Hours:
.91
-0.0057
-0.62%
Rein Therapeutics Inc stock is traded at $0.9157, with a volume of 2.06M.
It is up +5.87% in the last 24 hours and down -11.95% over the past month.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
See More
Previous Close:
$0.8649
Open:
$0.8864
24h Volume:
2.06M
Relative Volume:
3.04
Market Cap:
$78.33M
Revenue:
-
Net Income/Loss:
$-50.21M
P/E Ratio:
-0.4806
EPS:
-1.9053
Net Cash Flow:
$-16.61M
1W Performance:
-1.07%
1M Performance:
-11.95%
6M Performance:
-29.02%
1Y Performance:
-44.16%
1-Day Range:
$0.8649
$0.9299
1-Week Range:
$0.8641
$1.04
52-Week Range:
$0.8641
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
0.9157 | 73.98M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Yahoo Finance
Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com - Investing.com Nigeria
Rein Therapeutics (RNTX) Slips 1.6% as Stock Tests Key Support at $0.89Small Cap Breakouts - newsline.com
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherPost-Earnings Reaction - newsline.com
Rein Therapeutics enrolls 16 patients in lung fibrosis trial - Investing.com
Rein Therapeutics Expands Phase 2 RENEW Clinical Trial Into United Kingdom - marketscreener.com
RNTX Q1 2026 Earnings: Significant EPS Beat Highlights Cost Discipline as Pre-Revenue Biotech Advances PipelineInterim Report - newsline.com
Rein Therapeutics (NASDAQ: RNTX) 2026 proxy outlines share boost, director elections, pay - Stock Titan
RNTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Rein Therapeutics stock price target on dilution By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Rein Therapeutics (RNTX) Holds Steady at $1.11 as Stock Tests Key Support and Resistance LevelsDeath Cross - The Legal Advocate
Rein Therapeutics (RNTX) Holds Steady at $1.11 – Range-Bound Action Points to Key LevelsPCR Mean Reversion - The Legal Advocate
Rein Therapeutics (RNTX) Holds Steady at $1.11 Amid Low Volume ConsolidationCovered Call ETF - newsline.com
Rein Therapeutics director buys $49,560 in company stock By Investing.com - Investing.com Australia
Rein Therapeutics director buys $49,560 in company stock - Investing.com
Rein Therapeutics (RNTX) asks shareholders to double authorized shares to 200M - Stock Titan
Rein Therapeutics (RNTX) Slips Near Support; Key Levels TestedBackspread Trade - newsline.com
RNTX Q1 2026 Earnings: EPS Beats Estimates as Preclinical Stage Biotech Tightens SpendingAnalyst Consensus Shift - Newser
RNTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Rein Therapeutics Advances PipelineProfit Growth Outlook - Newser
RNTX Q1 2026 Earnings: Narrower‑than‑expected Loss Fails to Lift SharesEarnings Acceleration Picks - newsline.com
Rein Therapeutics (RNTX) Surges 7% as Stock Tests Key Resistance at $1.09Community Risk Signals - newser.com
Rein Therapeutics (RNTX) Q1 2026 Earnings Surprise: EPS $-0.19, Up SignificantHigh Estimate Range - Newser
Rein Therapeutics closes $57.5 million stock offering By Investing.com - Investing.com Nigeria
Rein Therapeutics announces closing of $57.5 million underwritten public offering - marketscreener.com
Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering - TradingView
Rein Therapeutics closes $57.5 million stock offering - Investing.com
Biotech Rein Therapeutics raises $57.5M for lung fibrosis trial - Stock Titan
Rein Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics, Inc. 1Q 2026: Revenue $0 Net loss $(5.84)M, EPS $(0.19) — 10-Q Summary - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
RNTX Technical Analysis | Trend, Signals & Chart Patterns | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
Rein Therapeutics CEO Windsor buys $25,000 in common stock By Investing.com - Investing.com Nigeria
Rein Therapeutics CEO Windsor buys $25,000 in common stock - Investing.com
Rein Therapeutics (RNTX) quarterly results lack key metrics as company navigates strategic positioning, investors await clarityMomentum Score - newser.com
Number of shareholders of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Rein Therapeutics, Inc. News — NASDAQ:RNTX - TradingView
Should you add Rein Therapeutics (RNTX) to your watchlist today? (Trend Strengthens) 2026-05-08Viral Trade Signals - newser.com
Bios/Cavu investors disclose ~9.99% stake in Rein Therapeutics (RNTX) via preferred conversions - Stock Titan
Lynwood group owns 4.75M Rein Therapeutics (RNTX) shares (6.1%) - Stock Titan
Funicular Funds holds 5.195M shares in Rein Therapeutics (RNTX) — 6.7% - Stock Titan
Rein Therapeutics(RNTX) Stock Options Chain | Quotes & News - Moomoo
L. Lytton reports 4.5M shares in Rein Therapeutics (NASDAQ: RNTX) - Stock Titan
Rein Therapeutics, Inc.Common Stock (Nasdaq:RNTX) Stock Quote - The Chronicle-Journal
Rein Therapeutics Prices $50 Million Public Equity Offering - The Globe and Mail
Rein Therapeutics (NASDAQ: RNTX) raises $50M, funds IPF trial into 2028 - Stock Titan
Rein Therapeutics (NASDAQ: RNTX) to sell 50M shares, nets ~$46.1M - Stock Titan
Rein Therapeutics stock dips after pricing $50M share offering - MSN
Rein Therapeutics Inc Stock (RNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):